Using two platforms, Ventus expands the set of targets amenable to small-molecule medicines including targets which have never been drugged and others for which existing chemical matter leaves significant room for improvement.

The company is advancing a pipeline of new medicines to treat autoimmune and inflammatory diseases, neurological disorders, and cancer.